Definium Therapeutics (NASDAQ:DFTX) Rating Increased to Strong-Buy at Wolfe Research

Wolfe Research upgraded shares of Definium Therapeutics (NASDAQ:DFTX) to a strong-buy rating in a research note published on Monday, Marketbeat reports.

A number of other equities analysts also recently issued reports on the company. Chardan Capital upgraded Definium Therapeutics to a “strong-buy” rating in a report on Wednesday, November 19th. Royal Bank Of Canada lifted their price target on shares of Definium Therapeutics from $20.00 to $36.00 and gave the company an “outperform” rating in a research report on Friday, January 23rd. Jefferies Financial Group assumed coverage on shares of Definium Therapeutics in a research note on Thursday, January 29th. They set a “buy” rating and a $30.00 price objective on the stock. Robert W. Baird set a $37.00 target price on shares of Definium Therapeutics in a research note on Thursday, January 29th. Finally, Canaccord Genuity Group boosted their price target on Definium Therapeutics from $16.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Definium Therapeutics presently has an average rating of “Buy” and an average target price of $34.20.

Definium Therapeutics Stock Up 2.9%

DFTX stock opened at $17.45 on Monday. Definium Therapeutics has a fifty-two week low of $4.70 and a fifty-two week high of $18.70. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of -8.55 and a beta of 2.57. The business’s 50 day moving average price is $15.36 and its two-hundred day moving average price is $12.69. The company has a debt-to-equity ratio of 0.31, a quick ratio of 3.30 and a current ratio of 3.30.

Insiders Place Their Bets

In other news, insider Mark Sullivan sold 11,276 shares of the company’s stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $148,279.40. Following the transaction, the insider owned 282,576 shares in the company, valued at approximately $3,715,874.40. This represents a 3.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Robert Barrow sold 25,791 shares of the stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $13.15, for a total transaction of $339,151.65. Following the sale, the chief executive officer owned 778,477 shares in the company, valued at approximately $10,236,972.55. The trade was a 3.21% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 42,667 shares of company stock valued at $561,071. Insiders own 2.26% of the company’s stock.

Hedge Funds Weigh In On Definium Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of DFTX. Royal Bank of Canada boosted its holdings in shares of Definium Therapeutics by 10.4% during the 1st quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock valued at $382,000 after acquiring an additional 6,148 shares during the last quarter. CWM LLC lifted its position in Definium Therapeutics by 67.4% during the second quarter. CWM LLC now owns 4,459 shares of the company’s stock valued at $29,000 after purchasing an additional 1,796 shares during the period. Teacher Retirement System of Texas lifted its position in Definium Therapeutics by 9.4% during the second quarter. Teacher Retirement System of Texas now owns 16,260 shares of the company’s stock valued at $106,000 after purchasing an additional 1,400 shares during the period. Geode Capital Management LLC boosted its holdings in Definium Therapeutics by 4.0% in the second quarter. Geode Capital Management LLC now owns 1,733,454 shares of the company’s stock worth $11,252,000 after purchasing an additional 66,663 shares during the last quarter. Finally, Creative Planning grew its position in Definium Therapeutics by 2.6% in the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock worth $429,000 after purchasing an additional 1,655 shares during the period. Institutional investors own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.